Boehringer Ingelheim commits up to $1B for AI-driven RNA splicing targets

Boehringer Ingelheim commits up to $1B for AI-driven RNA splicing targets

Boehringer Ingelheim has entered a partnership with Envisagenics that could reach more than $1 billion in total value, aiming to exploit what the companies describe as an underutilized source of cancer drug targets: aberrant RNA splicing events specific to tumor cells.

Under the agreement announced in September 2026, New York–based Envisagenics will deploy its AI platform to screen for and validate cancer-specific RNA alterations. Boehringer Ingelheim will then have the option to license select targets and advance them through development using precision oncology modalities including multi-specific antibodies, antibody-drug conjugates, and T cell engagers.

The deal structure includes an undisclosed upfront payment, research funding, option fees, and milestone payments tied to development, regulatory approval, and commercial sales. Envisagenics will also receive royalties on any products that reach the market, according to details first reported by BioSpace.

Targeting dysregulated splicing in aggressive tumors

RNA splicing is the cellular process by which non-coding sequences are removed from messenger RNA molecules before they direct protein synthesis. In cancer, this mechanism can become dysregulated, producing oncogenic errors that drive uncontrolled cell division and tumor growth.

Envisagenics CEO Maria Pineda confirmed that the two organizations will collaborate closely on target validation studies. Once validated, Boehringer Ingelheim will assume full responsibility for selecting the therapeutic modality, conducting development work, and commercializing any resulting treatments. The pharma's focus, Pineda noted, is on aggressive solid tumors with significant unmet medical need and limited existing treatment options.

Why it matters

RNA splicing represents a relatively untapped frontier in precision oncology. While most targeted cancer therapies focus on mutations in DNA or overexpressed proteins, splicing alterations create tumor-specific molecular signatures that may be invisible to conventional drug discovery approaches. AI-enabled platforms like Envisagenics' can systematically identify these events at scale, potentially unlocking a new class of targets for biologics and other precision tools. The deal's size—exceeding $1 billion—signals growing pharma confidence that splicing biology can yield commercially viable therapies, not just academic curiosities.

Growing interest in splicing-targeted therapies

Boehringer Ingelheim and Envisagenics join a expanding cohort of companies pursuing splicing biology as a therapeutic avenue. Skyhawk Therapeutics is developing small-molecule drugs designed to modify disease-causing spliced RNA, with applications in both oncology and neurology. In August 2025, Merck KGaA committed over $2 billion in potential deal value to partner with Skyhawk on RNA modulators for neurological conditions.

Another player, Rgenta Therapeutics, is engineering small-molecule glues that mark improperly spliced RNA for cellular degradation, targeting both cancer and central nervous system disorders.

The convergence of AI-driven target discovery and advanced biologics manufacturing is enabling pharma to pursue molecular targets that would have been impractical or invisible a decade ago. Boehringer's investment suggests the company views splicing alterations as a competitive differentiator in the crowded oncology landscape.

Details of the partnership were first reported by BioSpace.